Supernus Pharmaceuticals Dirección
Dirección controles de criterios 2/4
El CEO de Supernus Pharmaceuticals es Jack Khattar , nombrado en Jan 2005, tiene una permanencia de 19.83 años. compensación anual total es $13.28M, compuesta por 7.3% salario y 92.7% primas, incluidas acciones y opciones de la empresa. posee directamente un 3.53% de las acciones de la empresa, por valor de $70.38M. La antigüedad media del equipo directivo y de la junta directiva es de 9.6 años y 12.3 años, respectivamente.
Información clave
Jack Khattar
Chief Executive Officer (CEO)
US$13.3m
Compensación total
| Porcentaje del salario del CEO | 7.3% |
| Permanencia del CEO | 19.8yrs |
| Participación del CEO | 3.5% |
| Permanencia media de la dirección | 9.6yrs |
| Promedio de permanencia en la Junta Directiva | 12.3yrs |
Actualizaciones recientes de la dirección
Recent updates
Supernus Pharmaceuticals: Recently Launched Qelbree Is Powering Growth
Nov 12Supernus Pharmaceuticals, Inc.'s (NASDAQ:SUPN) Share Price Could Signal Some Risk
Oct 31
Supernus: Stock Slides As Qelbree Sales Questioned, But Positives Still Outweigh Negatives
Sep 12Supernus Pharmaceuticals' (NASDAQ:SUPN) Conservative Accounting Might Explain Soft Earnings
Aug 19Supernus Pharmaceuticals: So-So Neuroscience Portfolio, With ADHD Standout
Jul 02Subdued Growth No Barrier To Supernus Pharmaceuticals, Inc.'s (NASDAQ:SUPN) Price
Apr 24Supernus Pharmaceuticals: Moving Through An 'Inflection Year'
Mar 04We Think Supernus Pharmaceuticals (NASDAQ:SUPN) Can Stay On Top Of Its Debt
May 10Does Supernus Pharmaceuticals (NASDAQ:SUPN) Have A Healthy Balance Sheet?
Feb 03These 4 Measures Indicate That Supernus Pharmaceuticals (NASDAQ:SUPN) Is Using Debt Reasonably Well
Oct 19Supernus stock falls 12.6% after FDA declines to approve Parkinson’s disease treatment
Oct 10Supernus Pharmaceuticals: Deep Expertise In CNS, Eyes On Qelbree Launch And Parkinson Portfolio
Aug 19Supernus Pharmaceuticals' (NASDAQ:SUPN) Soft Earnings Are Actually Better Than They Appear
Aug 16Supernus: A Work In Progress
Jul 29Supernus: New Beginnings
Mar 28Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | US$60m |
| Jun 30 2024 | n/a | n/a | US$5m |
| Mar 31 2024 | n/a | n/a | -US$16m |
| Dec 31 2023 | US$13m | US$963k | US$1m |
| Sep 30 2023 | n/a | n/a | US$26m |
| Jun 30 2023 | n/a | n/a | US$43m |
| Mar 31 2023 | n/a | n/a | US$52m |
| Dec 31 2022 | US$10m | US$914k | US$61m |
| Sep 30 2022 | n/a | n/a | US$38m |
| Jun 30 2022 | n/a | n/a | US$57m |
| Mar 31 2022 | n/a | n/a | US$73m |
| Dec 31 2021 | US$8m | US$870k | US$53m |
| Sep 30 2021 | n/a | n/a | US$82m |
| Jun 30 2021 | n/a | n/a | US$100m |
| Mar 31 2021 | n/a | n/a | US$111m |
| Dec 31 2020 | US$7m | US$836k | US$127m |
| Sep 30 2020 | n/a | n/a | US$129m |
| Jun 30 2020 | n/a | n/a | US$118m |
| Mar 31 2020 | n/a | n/a | US$116m |
| Dec 31 2019 | US$8m | US$812k | US$113m |
| Sep 30 2019 | n/a | n/a | US$106m |
| Jun 30 2019 | n/a | n/a | US$105m |
| Mar 31 2019 | n/a | n/a | US$103m |
| Dec 31 2018 | US$7m | US$724k | US$111m |
| Sep 30 2018 | n/a | n/a | US$99m |
| Jun 30 2018 | n/a | n/a | US$87m |
| Mar 31 2018 | n/a | n/a | US$73m |
| Dec 31 2017 | US$6m | US$614k | US$57m |
Compensación vs. Mercado: La compensación total de Jack($USD13.28M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD5.38M).
Compensación vs. Ingresos: La compensación de Jack ha aumentado más de un 20% en el último año.
CEO
Jack Khattar (63 yo)
19.8yrs
Permanencia
US$13,278,093
Compensación
Mr. Jack A. Khattar, M.B.A., founded Supernus Pharmaceuticals, Inc. (Formerly, Shire Laboratories, Inc.) in 2005 and has served as Chief Executive Officer, President, Secretary and Director since 2005. He...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Founder | 19.8yrs | US$13.28m | 3.53% $ 70.4m | |
| Senior VP & CFO | 3.3yrs | US$2.38m | 0.013% $ 259.7k | |
| Chief Scientific Officer & Senior VP of Intellectual Property | 12.7yrs | US$1.47m | 0.018% $ 349.6k | |
| Senior Vice President of Quality | 4.8yrs | US$1.79m | 0.015% $ 296.2k | |
| Senior VP of Research & Development and Chief Medical Officer | 4.8yrs | US$1.59m | 0.0084% $ 167.5k | |
| Compliance Officer | 12.8yrs | sin datos | sin datos | |
| Senior Vice President of Marketing | 9.8yrs | sin datos | sin datos | |
| Senior Vice President of Sales | 9.8yrs | sin datos | sin datos | |
| Senior Vice President of Corporate Development | 9.3yrs | sin datos | sin datos | |
| Senior Vice President of Supply Chain | 3.5yrs | sin datos | sin datos |
9.6yrs
Permanencia media
63yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de SUPN es experimentado (9.6 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Founder | 19.8yrs | US$13.28m | 3.53% $ 70.4m | |
| Independent Chairman of the Board | 19.8yrs | US$407.02k | 0.24% $ 4.7m | |
| Independent Director | 9.7yrs | US$378.52k | 0.024% $ 480.9k | |
| Independent Director | 6.4yrs | US$376.02k | 0.031% $ 621.3k | |
| Independent Director | 14.8yrs | US$385.02k | 0.051% $ 1.0m | |
| Director | less than a year | US$514.39k | sin datos |
12.3yrs
Permanencia media
63.5yo
Promedio de edad
Junta con experiencia: Los miembros de la junta directiva de SUPN son experimentados ( 12.3 años antigüedad media).